M

Meenakshi Mission Hospital and Research Centre | Clinical Research Department

Research site

(Unclaimed)

Location

Lake area, Melur Road, Madurai, Tamil Nadu, India

Site insights

Top conditions

Top treatments

Paclitaxel

Trastuzumab

Dexamethasone

Cisplatin

MEZIVd

BMS-986012

Cyclophosphamide

PF-05280014

BMS-986489

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 9 total trials

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (M...

Active, not recruiting

Anemia in Myelodysplastic Syndromes

Myelodysplastic Syndrome

Drug: HT-6184

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with...

Enrolling

Extensive-Stage Small Cell Lung Cancer

Drug: Carboplatin

Drug: Etoposide

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Pomalidomide

Drug: mezigdomide